Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 220 | 14% |
| 2020 | 3 | 183 | 15% |
| 2021 | 3 | 187 | 19% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maryland; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 10 | 326+15%/yr | +15%/yr | 0.40.8× | 0% | 570 in 2030+9.9%/yr |
| Stroke thrombectomy |
CSF shunts in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
| ≈ 140 |
| – |
| 2026 est. | ≈ 140 | – |
| 2022 | 2 | 188 | 22% |
| 2023 | 2 | 158 | 25% |
| 2024 | 3 | 162 | 28% |
| 2025 from claims | – | 139 112–163 | 29% |
| 2026 forecast | – | 143 112–179 | 29% |
| 2027 forecast | – | 145 107–191 | 29% |
| 2028 forecast | – | 147 104–203 | 30% |
| 2029 forecast | – | 149 101–213 | 31% |
| 2030 forecast | – | 151 99–224 | 31% |
In 2025, 100% inpatient hospital.
| −4.6%/yr |
| 0.2 |
| 0% |
| 540 in 2030+2.2%/yr |
| North Carolina | 2 | 190−7.9%/yr | −7.9%/yr | 0.2 | 0% | 170 in 2030−1.6%/yr |
| Tennessee | 2 | 130−2.8%/yr | −2.8%/yr | 0.2 | 0% | 130 in 2030+0.4%/yr |
| Virginia | 3 | 129−7.5%/yr | −7.5%/yr | 0.1 | 0% | 170 in 2030+4.6%/yr |
| Louisiana | 1 | 126−3%/yr | −3%/yr | 0.3 | 0% | 260 in 2030+13%/yr |
| Georgia | 0 | 123−9.2%/yr | −9.2%/yr | 0.1 | 0% | 180 in 2030+6.5%/yr |
| 13 |
| 289+7.1%/yr |
| +7.1%/yr |
| 0.30.8× |
| 0% |
| 580 in 2030+12%/yr |
| DBS & VNS | 1 | 111−4.1%/yr | −4.1%/yr | 0.10.4× | 0% | 120 in 2030+1.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 54% of company spending on these surgeons in 2025, −33 pts on 2024.
In 2025, 6 companies reported engagement with Maryland’s surgeons worth $51K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.